Scarica l'app Stockscreener
39.18
4.56%
-1.87
Precedente Chiudi:
$41.05
Aprire:
$41.74
Volume 24 ore:
846.22K
Relative Volume:
1.16
Capitalizzazione di mercato:
$3.29B
Reddito:
$399.58M
Utile/perdita netta:
$-54.04M
Rapporto P/E:
-52.24
EPS:
-0.75
Flusso di cassa netto:
$40.13M
1 W Prestazione:
-4.69%
1M Prestazione:
-10.14%
6M Prestazione:
+23.87%
1 anno Prestazione:
+59.66%
Intervallo 1D:
$38.44
$41.81
Intervallo di 1 settimana:
$38.44
$42.34
Portata 52W:
$18.61
$47.32
Veracyte Inc Stock (VCYT) Company Profile
Nome
Veracyte Inc
Settore
Industria
Telefono
(650) 243-6300
Indirizzo
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Confronta VCYT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
39.18 | 3.29B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
532.55 | 203.70B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.23 | 151.18B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
135.37 | 38.62B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
452.77 | 37.07B | 3.90B | 887.87M | 808.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
191.04 | 33.64B | 15.41B | 1.37B | 2.11B | 7.50 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-05 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-16 | Iniziato | UBS | Buy |
| 2024-10-10 | Iniziato | Guggenheim | Buy |
| 2024-02-23 | Reiterato | Needham | Buy |
| 2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2021-11-18 | Ripresa | Goldman | Buy |
| 2021-06-15 | Iniziato | Raymond James | Outperform |
| 2021-02-18 | Ripresa | Needham | Buy |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | Iniziato | Morgan Stanley | Underweight |
| 2019-07-31 | Iniziato | Lake Street | Buy |
| 2019-07-02 | Iniziato | Needham | Buy |
| 2018-11-29 | Downgrade | Janney | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Janney | Neutral → Buy |
| 2017-11-07 | Downgrade | Janney | Buy → Neutral |
| 2017-11-07 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | Ripresa | BTIG Research | Buy |
| 2016-11-14 | Ripresa | Leerink Partners | Outperform |
| 2015-12-18 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-06-11 | Reiterato | Leerink Partners | Outperform |
| 2013-11-26 | Iniziato | William Blair | Outperform |
Mostra tutto
Veracyte Inc Borsa (VCYT) Ultime notizie
Is Veracyte Stock a Good Addition to Your Portfolio Right Now? - Nasdaq
Veracyte (VCYT) Expected to Announce Quarterly Earnings on Monday - MarketBeat
8,074 Shares in Veracyte, Inc. (NASDAQ:VCYT) Acquired by Convergence Investment Partners LLC - MarketBeat
Veracyte to Participate in Upcoming Investor Conferences - WICZ
Can Veracyte's March Conference Circuit Signal Major Strategic Updates? - StockTitan
Rice Hall James & Associates LLC Decreases Holdings in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
The Latest Breaking News from VCYT - Inkl
VCYT: 3 Emerging Biotech Firms Pioneering Next-Gen Therapies - StockNews.com
Veracyte, Inc. (NASDAQ:VCYT) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Veracyte (NASDAQ:VCYT) Cut to “Hold” at StockNews.com - Defense World
Veracyte Stock Soars to 52-Week High, Reaching $46.12 - MSN
Veracyte (NASDAQ:VCYT) Upgraded by StockNews.com to Buy Rating - MarketBeat
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research - 01Net
Veracyte (NASDAQ:VCYT) Trading Down 7.1%What's Next? - MarketBeat
Sumitomo Mitsui Trust Group Inc. Sells 259,006 Shares of Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium - BioSpace
Veracyte, Inc. (NASDAQ:VCYT) CFO Rebecca Chambers Sells 527 Shares - MarketBeat
Jennison Associates LLC Raises Stock Position in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Blue Trust Inc. Cuts Position in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte CFO Rebecca Chambers sells $23,108 in stock - MSN
KBC Group NV Boosts Stock Position in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Caprock Group LLC Sells 555 Shares of Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte CFO Rebecca Chambers sells $23,108 in stock By Investing.com - Investing.com Australia
Insider Sell: Rebecca Chambers Sells Shares of Veracyte Inc (VCY - GuruFocus.com
Veracyte CFO Sells Shares Under Pre-arranged Trading Plan - TradingView
New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer - BioSpace
Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025 - Business Wire
Veracyte (NASDAQ:VCYT) Sets New 52-Week High After Analyst Upgrade - MarketBeat
6,621 Shares in Veracyte, Inc. (NASDAQ:VCYT) Purchased by Baader Bank Aktiengesellschaft - MarketBeat
Veracyte (NASDAQ:VCYT) Rating Lowered to Hold at StockNews.com - MarketBeat
Needham & Company LLC Issues Positive Forecast for Veracyte (NASDAQ:VCYT) Stock Price - MarketBeat
Veracyte Stock Soars to 52-Week High, Reaching $46.12 By Investing.com - Investing.com Australia
Veracyte (NASDAQ:VCYT) Sets New 52-Week High on Analyst Upgrade - Defense World
Veracyte stock price target raised to $51 at Needham - MSN
Veracyte Inc Azioni (VCYT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Veracyte Inc Azioni (VCYT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| EPSTEIN ROBERT S | Director |
Jan 06 '25 |
Option Exercise |
8.04 |
20,000 |
160,800 |
64,598 |
| EASTHAM KARIN | Director |
Jan 02 '25 |
Option Exercise |
5.28 |
10,000 |
52,800 |
28,497 |
| EASTHAM KARIN | Director |
Jan 02 '25 |
Sale |
40.30 |
10,000 |
403,006 |
18,497 |
0.06%
3.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):